Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 129,237

Document Document Title
WO/2018/023009A1
This invention relates to deuterated forms of hexahydro-4,7-methano-1H-isoindole-1,3(2H)-diones, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I): or a pharmaceutically accept...  
WO/2018/022604A4
The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochond...  
WO/2018/022604A3
The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochond...  
WO/2018/022815A3
Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.  
WO/2018/022848A1
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg.  
WO/2018/022529A1
Compounds having the following formula (I): Formula I and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurolo...  
WO/2018/022817A1
A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises drug reservoir layer comprised of an acrylate copolymer, glycerine, and donepezil base generated in situ by reaction of donepezil H...  
WO/2018/021977A1
The present invention relates to a compound of general formula (I) and/or its solvates, hydrates and pharmaceutically acceptable salts, which are modulators of glycine metabolism. The present invention also relates to the methods for the...  
WO/2018/020010A1
The invention relates to the use of biotin at a daily dose of at least 100 mg for treating hepatic encephalopathy.  
WO/2018/019823A8
The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their intera...  
WO/2018/020491A1
The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, ginkgo biloba, and β-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said comp...  
WO/2018/018138A1
Methods and kits for accurate determination of salivary levels of Abeta42 are provided. A method of analysing a saliva sample includes the steps of obtaining the saliva sample from a subject; stabilizing the saliva sample; measuring the ...  
WO/2018/022664A1
Described herein are methods for treating a subject having or at risk of developing an autoimmune or inflammatory condition or an infection by administering a neuromodulating agent.  
WO/2018/018152A1
An orally administrable chewing gum formulation is provided comprising a pharmaceutically acceptable gum base and particles of a pharmaceutical agent ranging in size from about 50 to about 2000 µm, wherein the formulation comprises abou...  
WO/2018/019823A1
The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their intera...  
WO/2018/021447A1
The purpose of the present invention is to provide a novel compound having D3 receptor antagonistic effect. Provided are the following: a compound represented by formula (I) (in the formula, ring A is a heterocyclic ring, X1 groups are e...  
WO/2018/022664A8
Described herein are methods for treating a subject having or at risk of developing an autoimmune or inflammatory condition or an infection by administering a neuromodulating agent.  
WO/2018/019681A1
There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, s...  
WO/2018/020013A1
The invention relates to a plant extract comprising a concentration, measured by the HPLC method, of at least 0.2 wt.% of safranal in relation to the total weight of the dry material. The invention also relates to a method for producing ...  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/023036A1
A method of treating or preventing amyloid related imaging abnormalities (ARIA) in patients receiving one or more course of medical treatment for Alzheimer's Disease includes administrating a SUR1-TRPM4 channel inhibitor, such as glyburi...  
WO/2018/022816A1
Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.  
WO/2018/022818A1
Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, whe...  
WO/2018/021471A1
The purpose of the present invention is to provide a food material that has a brain-function improving function, that has a high storage stability, and that can be ingested at a low cost. It was found that a walnut-protein hydrolyzate th...  
WO/2018/019996A1
The present invention includes: - The association of hyaluronic acid tetrasaccharides HA4 with pentacyclic triterpenes that can be obtained from plants such as Burseraceae, Oleaceae, Apiaceae, and their derivatives. - The optional furthe...  
WO/2018/020242A1
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compound...  
WO/2018/019166A1
Provided are salts of 2, 6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.  
WO/2018/023035A1
A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by admini...  
WO/2018/022814A1
A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for t...  
WO/2018/014277A1
The present invention relates to a rotigotine behenate and a manufacturing method and application thereof, and provides a method for manufacturing the rotigotine behenate and an application of the rotigotine behenate in treating a diseas...  
WO/2018/014880A1
Provided are a vortioxetine analogue as shown in formula I or a polymorph or a solvate thereof, a composition and a kit comprising the analogue, polymorph or solvate, the use of the analogue, polymorph or solvate in the preparation of a ...  
WO/2018/014225A1
The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS 128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method o...  
WO/2018/017711A1
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.  
WO/2018/014802A1
The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compoun...  
WO/2018/015861A1
The use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject with a blood or serum CRP level of less than 10 mg/L. The disclosure also discloses the use of 1-MNA or a pharmac...  
WO/2018/015868A1
The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical sympt...  
WO/2018/017850A1
The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharm...  
WO/2018/015445A1
The present invention relates to compounds of Formula (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturati...  
WO/2018/017767A1
Example systems, methods, and apparatus, including cognitive platforms, are provided for applying signal detection metrics in computer-implemented adaptive response-deadline procedures to data collected based at least in part on user int...  
WO/2018/015945A3
Described herein are mesenchymal stem cells and populations thereof, which can be used for treating neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) disease. Methods for treating neurodegenerative diseases, such as...  
WO/2018/014834A1
Disclosed are a 3-hydrocarbyl-5,6-dioxy-substituted phthalide compound and a preparation method and use thereof. The structure of the phthalide compound is as shown in formula (I): wherein the definitions of R1, R2 and R3 are as describe...  
WO/2018/015235A1
The present invention relates to compounds of formulas IA and IB IA IB or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer the...  
WO/2018/015558A1
The invention relates to a new class of substituted indole derivatives that are able to activate 5-HT7 serotonin receptor. These compounds bind 5-HT7 serotonin receptor with high affinity and selectivity, while possessing favourable phys...  
WO/2018/015862A1
Disclosed therein is a method for raising circulating adiponectin levels or treating diseases or disorders mediated by insufficient production of adiponectin in a subject, e.g. human, comprising administering to the subject 1-MNAor a pha...  
WO/2018/016547A1
The present invention addresses the problem of providing a novel compound which has an antagonistic activity against CGRP receptors and is useful for the treatment of various diseases associated with CGRP receptors. That is, the present ...  
WO/2018/014770A1
The present invention relates to a phenol-containing derivative, an etomidate pharmaceutical composition, a preparation method thereof, and application of same in the field of central nervous system treatment. A phenol derivative is a co...  
WO/2018/016657A1
The invention provides a compound of ethyl 6- [ (2-chloro- 4-fluorophenyl)methanesulfonyl] -3-methylcyclohex-1-ene-1- carboxylate. The compound possesses an advantageous combination of TLR4 antagonist properties and brain permeability, a...  
WO/2018/015088A1
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2018/017896A1
The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful...  
WO/2018/015945A2
Described herein are mesenchymal stem cells and populations thereof, which can be used for treating neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) disease. Methods for treating neurodegenerative diseases, such as...  

Matches 401 - 450 out of 129,237